Icalcaprant is under clinical development by Cerevel Therapeutics and currently in Phase I for Bipolar I Disorder.

Shares in AbbVie have slumped after a pair of failed ... Cerevel's pipeline behind emraclidine includes tavapadon, a dopamine D1/D5 partial agonist in phase 3 testing as a treatment for Parkinson ...

AbbVie (ABBV) closed at $177.70 in the latest trading session, marking a +0.85% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.43% for the day. On the other ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other dividend growth stocks. Dividend stocks had a challenging year in 2024 as investor interest ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other long-term stocks. To select stocks with long-term growth potential, investors should focus on ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

This page features the latest news about the Abbvie stock. AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call NORTH CHICAGO, Ill., Jan. 3, 2025 /PRNewswire/ -- AbbVie (NYSE ...